Roundup of findings reported at ASRS 39th Annual Scientific Meeting

A review of studies, presentations and discussions at ASRS 2021 in San Antonio, Texas.

The American Society of Retina Specialists (ASRS) hosted its 39th Annual Scientific Meeting from October 8-12, 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.

The 2021 scientific program offered attendees innovations in retina science, clinical practice, and surgery with 148 papers, 165 posters, 46 papers on demand, and 69 films, as well as a wide range of networking opportunities and the chance to exchange ideas and perspectives with peers. Here is a review of the presentations covered by Modern Retina®.

Age-related macular degeneration

Study details Port Delivery System with ranibizumab in nAMD

In a presentation at the American Society of Retina Specialists 2021 annual meeting, Arshad Khanani, MD, MA, noted that investigators achieved results similar to those in patients treated with monthly ranibizumab injections for neovascular age-related macular degeneration.

OAKS and DERBY studies demonstrate efficacy of pegcetacoplan for Geographic Atrophy

During the American Society of Retina Specialists 2021 annual meeting, David Boyer, MD, told attendees that pegcetacoplan used to treat geographic atrophy proved to be well tolerated by patients in the phase 3 DERBY and OAKS studies.

Diabetic eye disease

Diabetic retinopathy

PANORAMA study outlines variables to watch when managing NPDR

During a presentation at the American Society of Retina Specialists 2021 annual meeting in San Antonio, W. Lloyd Clark, MD, presented results of the PANORAMA Study. The focus of the study, Clark said, was to identify the factors that increase the risk of complications in patients with nonproliferative diabetic retinopathy to provide information for making decisions on treatment choices.

Diabetic macular edema

Determining the time to DME resolution with intravitreal aflibercept

Speaking at the American Society of Retina Specialists 2021 annual meeting in San Antonio, Rishi P. Singh, MD, provided results of the VISTA and VIVID studies, and he pointed out that the findings could help physicians set expectations of DME therapy.

Faricimab in DME: Results from phase 3 YOSEMITE and RHINE trials

Caroline Baumal, MD, provides an overview of the efficacy, safety and durability of faricimab in diabetic macular edema (DME) at ASRS 2021.

Imaging

Higher order OCT analysis for inflammatory signal biomarkers in the HAWK study

Justis P. Ehlers, MD, discusses the findings from a higher-order OCT analysis for inflammatory signal biomarkers in the HAWK Study.

Commercial OCT: Tracking macrophages in the macular circulation

Speaking at the American Society of Retina Specialists 2021 annual meeting, Richard B. Rosen, MD, DSc (Hon) noted that clinical OCT and offers a new clinical biomarker for tracking the onset and progression of retinal vascular disease and the response to therapy.

Uveitis

Dissecting real-world registry study of YUTIQ for chronic non-infectious posterior uveitis

Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.

Retinal Surgery

MIGS procedures and endophthalmitis

During a presentation at the American Society of Retina Specialists 2021 annual meeting in San Antonio, Texas, Yoshihiro Yonekawa, MD, warned of the potential risk of endophthalmitis with the use of implantable MIGS devices.

Ophthalmology

Masking risk of endophthalmitis after intravitreal anti-VEGF injections

During a presentation at American Society of Retina Specialists 2021 annual meeting in San Antonio, Sunir Garg, MD, presented data showing that universal masking does not seem to increase the risk of developing endophthalmitis, and it may cause a reduction in culture positive endophthalmitis.

Related Content: Additional ASRS 2021 Content | Conference Coverage | Ophthalmology